arrow
E

Enes Erul

ankara university
H指数:14
被引数:1,006

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

激素受体阳性、HER2阴性转移性乳腺癌中即刻与延迟使用CDK4/6抑制剂:一项真实世界研究

2026-08-290
OA
Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis

接受免疫检查点抑制剂治疗的癌症患者中的肌炎:ARON-MOUSEION-017系统评价与荟萃分析

2026-08-140
PRE
Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer

血清癌胚抗原水平在转移性非小细胞肺癌分子亚型中的分布及其临床和预后意义

2026-04-090
OA
Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

代谢功能障碍相关脂肪性肝病、胰岛素抵抗和肝细胞癌:一个致命的三联征

2025-10-100
OAAI
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

真实世界中曲磷胺或帕博西利联合氟维司群治疗激素受体阳性/HER2阴性转移性乳腺癌的疗效:土耳其肿瘤学组(TOG)研究

2025-03-040
PRE
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

瑞博西尼或帕博西尼联合来曲唑治疗激素受体阳性/HER2-negative转移性乳腺癌的疗效

2023-05-0310
PRE
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者中后续治疗的疗效 (第23卷,136,2023)

2023-02-272
OAAI